Interferon-based therapy for chronic hepatitis C: current and future perspectives (Q37288393)

19 August 2017

1 reference

title

Interferon-based therapy for chronic hepatitis C: current and future perspectives (English)

1 reference

19 August 2017

1 reference

1 reference

1 reference

1

Stefan Zeuzem

1 reference

PubMed ID

18838975

19 August 2017

language of work or name

English

0 references

publication date

7 October 2008

1 reference

Nature Reviews Gastroenterology & Hepatology

19 August 2017

1 reference

19 August 2017

5

1 reference

19 August 2017

11

1 reference

19 August 2017

610-622

1 reference

https://scigraph.springernature.com/pub.10.1038/ncpgasthep1274

19 August 2017

0 references

cites work

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

The way forward in HCV treatment--finding the right path

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Interferon-based therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

New kinetic models for the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Rapid virologic response: a new milestone in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Hepatitis C genotype 4: What we know and what we don't yet know.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Review article: predicting response in hepatitis C virus therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1274

7 January 2021

Identifiers

DOI

10.1038/NCPGASTHEP1274

1 reference

19 August 2017

1 reference

PubMed ID

18838975